D. Mark Hickinson

Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530

Tim P. Green, Mike Fennell, Robin Whittaker et al. · Molecular Oncology · 2009 · 254 citations · Full text

AZD8931, an Equipotent, Reversible Inhibitor of Signaling by Epidermal Growth Factor Receptor, ERBB2 (HER2), and ERBB3: A Unique Agent for Simultaneous ERBB Receptor Blockade in Cancer

D. Mark Hickinson, Teresa Klinowska, Georgina Speake et al. · Clinical Cancer Research · 2010 · 118 citations

Discovery of AZD8931, an Equipotent, Reversible Inhibitor of Signaling by EGFR, HER2, and HER3 Receptors

Bernard Barlaam, Judith Anderton, Peter Ballard et al. · ACS Medicinal Chemistry Letters · 2013 · 36 citations · Full text

Her3 Receptors, Molecular Biology, Tumor Biology +18

5-Substituted 4-anilinoquinazolines as potent, selective and orally active inhibitors of erbB2 receptor tyrosine kinase

Peter Ballard, Robert H. Bradbury, Laurent Hennequin et al. · Bioorganic & Medicinal Chemistry Letters · 2005 · 34 citations · Full text

Medicinal Chemistry, Biochemistry, Medicine +10

Neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase

Peter Ballard, Bernard Barlaam, Robert H. Bradbury et al. · Bioorganic & Medicinal Chemistry Letters · 2007 · 25 citations · Full text

Medicinal Chemistry, Neutral 5-Substituted 4-Anilinoquinazolines, Biochemistry +10